Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
P
PRCT
vs
S&P 500
S&P 500
Over the past 12 months, PRCT has underperformed S&P 500, delivering a return of -50% compared to S&P 500's +15% growth.
Stocks Performance
PRCT vs S&P 500
Performance Gap
PRCT vs S&P 500
Performance By Year
PRCT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Procept Biorobotics Corp
Glance View
Procept BioRobotics makes robotic medical devices for treating enlarged prostate, a common condition in older men. Its main product is the AQUABEAM system, which helps urologists remove extra prostate tissue using a precise waterjet guided by imaging and robotics. The company’s tools are used in hospitals and outpatient surgery centers where doctors perform these procedures. The business makes money in two main ways: it sells the robotic system to healthcare providers, and it also sells disposable parts, service, and support tied to each procedure. That creates a repeat revenue stream after the initial equipment sale. Its main customers are urologists, hospitals, and surgery centers that want a treatment option that can be less manual and more precise than older surgical methods. What makes Procept different is that it is not just another medical device seller; it sits between surgical robotics and urology. Instead of broad surgical use, it focuses on one specific procedure area and designs both the machine and the treatment workflow around it. That narrow focus gives the company a clear role in the care pathway for prostate enlargement treatments.